Apogee Minerals Ltd. (“Apogee” or the “Company” or the “Optionee”) (TSXV: APMI) announces that, further to its news release dated April 27, 2026, it has closed a non-brokered private placement ...

What Happened? A number of stocks jumped in the afternoon session after Oil prices fell sharply, a direct and immediate input ...

Apogee’s first quarter results were met with a positive market response, reflecting the company’s ability to navigate ...

The CEO of Apogee Therapeutics reported selling 20,000 shares of the company for approximately $1.50 million on March 11, 2026. This disposition represented 1.71% of Henderson's direct holdings at the ...

Q4 fiscal 2026. Management view "I'm pleased to share that our results for the quarter were ahead of our expectations on both the ...

Apogee Therapeutics, Inc. targets atopic dermatitis with APG777, aiming to outperform Dupixent through less frequent dosing and strong Phase 2 efficacy. APGE's recent $300M fundraising and analyst ...

Perceptive Advisors increased its Apogee Therapeutics position by 978,662 shares; the estimated trade value was $61.64 million (based on quarterly average prices). Meanwhile, the quarter-end position ...

Apogee Enterprises, Inc. (NASDAQ:APOG) shares are trading higher after the company reported second-quarter sales of $342.4 million, beating the consensus estimate of $335.3 million. Revenue fell 3.2% ...

Apogee Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of extended half-life monoclonal antibody therapeutics for inflammatory and immunological conditions ...

I tested the Kuru Apogee. With its 70s-style look and patented Kurusole tech, verified buyers say "I can walk for hours and ...